

**Description**

MRC2 Knockout A549 Cell Line is an A549 lung cancer cell line in which MRC2 (Mannose Receptor C-Type 2) is no longer expressed due to CRISPR/Cas9 genome editing. This cell line was generated by electroporation of A549 cells with ribonucleoprotein complexes of Cas9 with an sgRNA targeting MRC2.

This cell line has been validated by genomic sequencing and flow cytometry.

**Background**

MRC2 (Mannose Receptor C-Type 2) is an endocytic recycling receptor that binds collagen and collagen fragments from the extracellular matrix (ECM), targeting them for lysosomal degradation. This process plays a role in extracellular matrix remodeling. As a result, MRC2 deficiency in animal models has been correlated with increased fibrosis in organs including the lung, liver, and kidney. MRC2 is also upregulated in several types of cancer in humans, including a subset of breast cancers, prostate cancers, glioblastomas, acute myeloid leukemias (AML), and sarcomas. Increased MRC2 expression may contribute to increased tumor invasion and metastasis due to the degradation of the extracellular matrix in the tumor microenvironment (TME). Given its high expression in various cancer types and potential role in driving cancer progression, it will be of interest to develop antibody-drug conjugates (ADCs), CAR (chimeric antigen receptor)-T cells, or other therapies targeting MRC2.

**Application**

- Useful for testing MRC2-targeting therapies, including antibody-drug conjugates (ADCs) and CAR-T cells.
- Useful for studying phenotypes associated with MRC2 deficiency in a cellular model of human lung cells.

**Materials Provided**

Components	Format
2 vials of frozen cells	Each vial contains $\geq 1 \times 10^6$ cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

**Parental Cell Line**

A549 is a human lung alveolar vessel carcinoma cell line. Adherent epithelial cells.

**Mycoplasma Testing**

The cell line has been screened to confirm the absence of Mycoplasma species.

**Materials Required but Not Supplied**

These materials are not supplied with the cell line but are necessary for cell culture and cellular assays. BPS Bioscience's reagents are validated and optimized for use with this cell line and are highly recommended for best results. Media components are provided in the Media Formulations section below.

**Media Required for Cell Culture**

Name	Ordering Information
Thaw Medium 6	BPS Bioscience #60183

**Storage Conditions**

Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a  $-80^{\circ}\text{C}$  freezer for long term storage. Contact technical support at [support@bpsbioscience.com](mailto:support@bpsbioscience.com) if the cells are not frozen in dry ice upon arrival.

## Media Formulations

For best results, the use of validated and optimized media from BPS Bioscience is *highly recommended*. Other preparations or formulations of media may result in suboptimal performance.



Note: Thaw Media do *not* contain selective antibiotics. Cells should be grown at 37°C with 5% CO<sub>2</sub>. BPS Bioscience's cell lines are stable for at least 10 passages when grown under proper conditions.

### Media Required for Cell Culture

*Thaw Medium 6 (BPS Bioscience #60183):*

DMEM medium supplemented with 10% FBS, 1% Penicillin/Streptomycin.

## Cell Culture Protocol

**Note: A549 cells are derived from human material and thus the use of adequate safety precautions is recommended.**

### Cell Thawing

1. Swirl the vial of frozen cells for approximately 60 seconds in a 37°C water bath. As soon as the cells are thawed (it may be slightly faster or slower than 60 seconds), quickly transfer the entire contents of the vial to a tube containing 10 ml of pre-warmed Thaw Medium 6.


**Notes: Leaving the cells in the water bath at 37°C for too long will result in rapid loss of viability.**

2. Immediately spin down the cells at 300 x g for 5 minutes, remove the medium and resuspend the cells in 5 ml of pre-warmed Thaw Medium 6.
3. Transfer the resuspended cells to a T25 flask and incubate at 37°C in a 5% CO<sub>2</sub> incubator.
4. After 24 hours of culture, check for cell attachment and viability. Change medium to fresh Thaw Medium 6 and continue growing in a 5% CO<sub>2</sub> incubator at 37°C until the cells are ready to passage.
5. Replace media every 2-3 days until cells reach 90% confluency. At first passage and subsequent passages, use Thaw Medium 6.

### Cell Passage

1. Aspirate the medium, wash the cells with phosphate buffered saline (PBS) without Ca<sup>2+</sup>/Mg<sup>2+</sup>, and detach the cells from the culture vessel with 0.25% Trypsin/EDTA.
2. Once the cells have detached, add Thaw Medium 6 and transfer to a tube.
3. Spin down cells at 300 x g for 5 minutes, remove the medium and resuspend the cells in Thaw Medium 6.
4. Seed into new culture vessels at the recommended sub-cultivation ratio of 1:2 to 1:10 once or twice per week.





*Figure 2. Expression of MRC2 in the MRC2 Knockout A549 Cell Line by flow cytometry.* Cells were stained with PE-labeled Mouse Anti-Human CD280 (MRC2) antibody and analyzed by flow cytometry. Parental A549 cells are shown in blue, and MRC2 Knockout A549 cells are shown in red. Unstained parental A549 cells are shown in yellow. As a control, parental A549 cells were stained with PE Mouse IgG1,  $\kappa$  Isotype Control Antibody and shown in green. The y-axis shows the % of cells, while the x-axis represents the fluorophore intensity.

*Data shown is representative.*

#### License Disclosure

Visit [bpsbioscience.com/license](https://bpsbioscience.com/license) for the label license and other key information about this product.

#### Troubleshooting Guide

Visit [bpsbioscience.com/cell-line-faq](https://bpsbioscience.com/cell-line-faq) for detailed troubleshooting instructions. For lot-specific information and all other questions, please visit <https://bpsbioscience.com/contact>.

#### Notes

*The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.*

#### References

- Brundesmann M.M., *et al.*, 2011 *Am J Respir Cell Mol Biol* 46(2):233-239.  
 Chen R., *et al.*, 2025 *Blood* 146(Supplement 1):3291.  
 Kuo H-R., *et al.*, 2025 *JHEP Rep* 7(12):101601.  
 Evans R.J., *et al.*, 2023 *Mol Cancer Ther* 22(2):240-253.  
 Melander M.C., *et al.*, 2015 *Int J Oncol* 47(4):1177-1188.  
 Podolsky M.J., *et al.*, 2020 *JCI Insight* 5(10):e137519.

**Related Products**

<i>Products</i>	<i>Catalog #</i>	<i>Size</i>
Narsoplimab (Anti-MASP2 Antibody)	83974	1 mg/ 5 mg
CM-338 (Anti-MASP2 Antibody)	83977	1 mg/ 5 mg

*Version 030626*